Navigation Links
Biotech Company Relocates to State-of-the-Art Facility
Date:1/4/2011

HAMILTON, N.J., Jan. 4, 2011 /PRNewswire/ -- VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease-based targets or its partners' targets, announced today its relocation to a brand-new, state-of-the-art facility in Hamilton, NJ in Mercer County.

VENENUM Biodesign was established with the mission to improve patients' lives through the discovery of new therapeutic compounds. They are committed to building platforms for drug discovery research from novel targets to preclinical implementation. VENENUM Biodesign, a company within the Genesis Biotechnology Group, is located in "Einstein's Alley," the research and technology corridor in Hamilton, New Jersey. Their facility is easily accessible to other academic medical centers, biotech, and pharmaceutical companies in the New York, New Jersey, and Pennsylvania area.

This new facility is a unique blend of upscale office space with state-of-the-art laboratory facilities designed with a specialized floor plan to accommodate the Biodesign compound collection which includes 5.5 million proprietary compounds (the "ECLiPS" collection), six newly designed VENENUM Targeted Libraries (VTLs), and approximately 80,000 compounds from commercial sources. This small molecule collection is one of the largest in the world and, combined with state-of-the-art UHTS capabilities, is a powerful tool to generate quality platforms for drug discovery.

There are expansive laboratories to accommodate mammalian and yeast cell culture, siRNA technology, protein engineering and production, cellular reagent generation, structural biology, and in vitro assay and in vivo model development. VENENUM Biodesign's new facility has been engineered to specifically accommodate their well-published and experienced Target Biology department which identifies and validates novel targets. They are currently completing additional laboratory space immediately adjacent to the Target Biology Division to accommodate a growing Medicinal Chemistry team which implements and executes Hit-to-Lead and Lead Optimization programs.

According to Dr. Maria Webb, Chief Scientific Officer (CSO), "Our intention is to use our drug discovery capabilities to develop our own novel targets into therapeutic products as well as to provide access of our core capabilities to other companies and research institutions."

To find out more, please visit http://www.venenumbiodesign.com.Contact:Maria Webb, Ph.D.Chief Scientific Officer (CSO)mwebb@venenumbiodesign.com609.570.1048http://www.venenumbiodesign.com  This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE VENENUM Biodesign
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference
2. Interleukin Genetics, Inc. to Present at Biotech Showcase 2011
3. Reportlinker Adds Financial Health of Biotechnology and Drugs Industry in India and China
4. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
5. New Second Edition of Biotechnology and the Federal Circuit Examines the Courts Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases
6. Biotech Guru G. Steven Burrill Offers his Predictions on What Lies Ahead for the Biotech Industry in 2011
7. BioCrossroads Invests in Innovative Biotech Targeting Challenging Diseases
8. Reportlinker Adds Nanobiotechnologies- applications, markets and companies
9. Bunker Hill Community College Wins Major Endorsement for Biotechnology Courses
10. TriLink BioTechnologies Launches CleanAmp™ 7-deaza-dGTP for GC-rich Target Amplification
11. Reportlinker Adds Nanobiotechnology: Applications and Global Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... ... January 11, 2017 , ... Photonics industry and ... , are commending the U.S. Congress and President Obama for their recognition of ... of the American Innovation and Competitiveness Act (AICA). , The language of the ...
(Date:1/11/2017)... Yorba Linda, Ca (PRWEB) , ... January 11, ... ... antibiotic resistance in pathogens are observed in clinical settings, it is becoming increasingly ... ecological problem. An over-reliance on culture-based methods, the standard in the study of ...
(Date:1/11/2017)... ... January 11, 2017 , ... For many fledging startups, good ... challenges young businesses face. With the second installment of Quorum’s newest signature program, ... DiMasi, Founder and Principal of interactive design agency, P’unk Ave. , For ...
(Date:1/11/2017)... , ... January 11, 2017 , ... ... development professional has joined its team. Bernhard Bartylla will lead European initiatives for ... with Bernhard to introduce ACOMP and ARGEN to European manufacturers and researchers. Bernhard ...
Breaking Biology Technology:
(Date:12/15/2016)... AUBURN HILLS, Mich. , Dec. 15, 2016 /PRNewswire/ ... simply unlocking car doors or starting the engine. Continental ... 2017 in Las Vegas . Through ... PASE (Passive Start and Entry) and biometric elements, the ... the field of vehicle personalization and authentication. ...
(Date:12/8/2016)... Research Future published a half cooked research report on Mobile Biometric ... Market is expected to grow over the CAGR of ~35% during ... ... Mobile Biometric Security and Service Market is increasing at a ... security from unwanted cyber threats. The increasing use of mobile device ...
(Date:12/7/2016)... TEL AVIV, Israel , December 7, 2016 ... year with the expansion of its patent portfolio, which grew to over ... , , ... led by its recently filed patent entitled " System, Device, ... which covers technology that enables device makers to forego costly hardware components ...
Breaking Biology News(10 mins):